Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 14/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2200760 | 0.88 | EGLN1 (1.00) | EGLN1ALDH1A1 | |
| SCHEMBL7957180 | 0.88 | EGLN1 (0.80) | EGLN1KMT2AALDH1A1 | |
| SCHEMBL2201947 | 0.88 | EGLN1 (0.79) | EGLN1ALDH1A1 | |
| SCHEMBL2206131 | 0.88 | EGLN1 (1.00) | EGLN1ALDH1A1 | |
| SCHEMBL2204239 | 0.87 | EGLN1 (0.83) | EGLN1ALDH1A1 | |
| SCHEMBL2205303 | 0.87 | EGLN1 (0.74) | EGLN1ALDH1A1 | |
| SCHEMBL7957338 | 0.87 | EGLN1 (0.73) | EGLN1ALDH1A1 | |
| SCHEMBL2353779 | 0.87 | EGLN1 (0.60) | EGLN1KMT2ARPS6KB1 | |
| SCHEMBL2201315 | 0.84 | EGLN1 (1.00) | EGLN1KMT2AALDH1A1 | |
| SCHEMBL2203014 | 0.84 | EGLN1 (0.74) | EGLN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150218120-A1 | HIV INTEGRASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-06 | — | — | US | disclosed |
| US-20150218120-A1 | HIV INTEGRASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-06 | — | — | US | disclosed |
| US-20140142137-A1 | HIV INTEGRASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142137-A1 | HIV INTEGRASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (US) | 2014-05-22 | — | — | US | disclosed |
| WO-2012106534-A2 | HIV INTEGRASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142137-A1 | HIV INTEGRASE INHIBITORS | IMPDH1, TYMP, IMPA1 | EGLN1 2462/4885KMT2A 1460/4885ALDH1A1 1197/4885 |
| US-20150218120-A1 | HIV INTEGRASE INHIBITORS | IMPDH1, TYMP, IMPA1 | EGLN1 2462/4885KMT2A 1460/4885ALDH1A1 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.